20240208171546.png)
On March 25, the US Food and Drug Administration announced that the drug ipilimumab (brand name Yervoy) was approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.
Patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer. Memorial Sloan-Kettering's depth and breadth of experience managing all cancers means that patients get the best possible care no matter how uncommon their disease.
The US Food and Drug Administration announced today that the drug ipilimumab (brand name Yervoy) has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.
Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time — known as PSA velocity — is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.
Researchers at Memorial Sloan-Kettering Cancer Center’s Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.
An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma.
An international study led by researchers at Memorial Sloan-Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer.
A team of healthcare professionals at Memorial Sloan-Kettering Cancer Center has identified an efficient way to increase minority access to lifesaving colorectal cancer screening (CRCS) in communities where multiple barriers to preventive care exist.
A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies.
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Memorial Sloan-Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center, will provide leading-edge chemotherapy services to current MSKCC patients who live in or near Brooklyn — which amounts to more than 15 percent of MSKCC’s patients currently being treated in Manhattan. Many of these patients can now be spared the regular commute and receive their treatment in a more convenient setting designed to meet the special needs of chemotherapy patients and their caregivers.
The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. In an attempt to help physicians and patients weigh the risks and benefits of the available options, researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) are reporting in the Journal of Clinical Oncology on the development of a new prediction tool that calculates a patient’s individualized risk for recurrence five and ten years after surgery.
Recent studies have shown that acupuncture can help control a number of symptoms and side effects -- such as pain, fatigue, dry mouth, nausea, and vomiting -- associated with a variety of cancers and their treatments. Experts from Memorial Sloan-Kettering Cancer Center's Integrative Medicine Service, who have either conducted or reviewed many of those studies, recommend that cancer patients interested in acupuncture seek a certified or licensed acupuncturist who has training or past experience working with individuals with cancer.
About one-third of women diagnosed with early-stage breast cancer will have their cancer travel, or metastasize, to other parts of the body, with the bone being the most common site of initial detectable spread. Results from a recent retrospective study conducted by Memorial Sloan-Kettering Cancer Center investigators suggest that PET/CT scanning might offer the most efficient and effective detection of newly diagnosed breast cancer that has spread to the bone.
A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan-Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine.
Craig B. Thompson, MD, has been named the new President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center effective November 2, 2010.
The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. In an attempt to help physicians and patients weigh the risks and benefits of the available options, researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) are reporting in the Journal of Clinical Oncology on the development of a new prediction tool that calculates a patient’s individualized risk for recurrence five and ten years after surgery.
Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC’s new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.
Physician-scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) are studying a novel approach to treat metastatic melanoma, known as immunotherapy, which uses the body’s own immune system to attack cancer. Presented today at the American Society of Clinical Oncology (ASCO) annual meeting, encouraging new data shows – for the first time – a survival benefit in metastatic melanoma patients using an immunotherapy discovered and clinically investigated by researchers at Memorial Sloan-Kettering.
An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer (CRPC), known for its poor prognosis and limited treatment options. The research, led by investigators at Memorial Sloan-Kettering Cancer Center, appears early online and in an upcoming edition of The Lancet.
A Perspective piece in the New England Journal of Medicine calls for change in the way researchers and pharmaceutical companies collect and report adverse symptom information in clinical trials submitted to the Food and Drug Administration (FDA), and how the FDA represents this information on drug labels.
A “Perspective” piece in today’s New England Journal of Medicine by Peter B. Bach, MD, MAPP, points out that policy makers are relying on hospital ratings from the Dartmouth Atlas that could be misleading.
In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information. A new longitudinal study from researchers at Memorial Sloan-Kettering Cancer Center finds that while clinicians’ and patients’ reporting of treatment side effects are very different from each other, together they provide a more complete, clinically meaningful picture of the treatment experience.
There is concern that mastectomy is over-utilized in the United States, which raises questions about the role of surgeons and patient preference in treatment selection for breast cancer. New data from an observational study published in the October 14 issue of the Journal of the American Medical Association (JAMA).
The new Evelyn H. Lauder Breast Center of Memorial Sloan-Kettering Cancer Center (MSKCC) and the MSKCC Imaging Center have opened, offering patients the most advanced outpatient services for cancer diagnosis and breast cancer treatment and detection.
Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year’s Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center.
To address the special challenges of treating cancer in older patients, Memorial Sloan-Kettering recently established a Geriatrics Service in the Department of Medicine.
Investigators at Memorial Sloan-Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.
New research led by investigators at Memorial Sloan-Kettering Cancer Center sheds light on a genetic function that gives breast cancer cells the ability to survive and spread to the bone years after treatment has been administered. The findings support the study of therapies that target this survival capacity and force the death of latent breast cancer cells before they get a chance to metastasize. The research will be published in the July 7 issue of Cancer Cell.
A new study by researchers at Memorial Sloan-Kettering Cancer Center reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone "“ the two most prominent sites of lung cancer relapse. The study will be published online in the journal Cell on July 2.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right